Astec LifeSciences Limited (ASTEC) — FY26 Annual Report | 8 July 2026(2 announcements)

The Annual Report 2025-26 for Astec LifeSciences Limited (NSE: ASTEC) details FY2025-26 financial performance, strategic focus on CDMO expansion and sustainability, and governance updates including board changes effective April 13, 2026. Revenue rose to ₹44,814.56 lakh (up from ₹38,130.35 lakh), though net loss narrowed to ₹8,087.62 lakh from ₹13,471.17 lakh. Key highlights include EBITDA break-even, volume growth, capacity utilization, and a rights issue raising ₹249.35 Crore via 28,01,673 shares at ₹890 each. The board now comprises 10 directors with 5 independent members (1 woman), following the retirement of Mr. Nadir Godrej as Chairman and appointment of Mr. Vishal Sharma as Chairperson. Sustainability efforts include 26.7% renewable energy use, 800 MT waste diverted, and EcoVadis Gold rating. CDMO segment growth accelerated 2.5x in H2 FY2025-26, with capacity expansion planned to capture a $4.1B off-patent active ingredients market opportunity. The report confirms no material regulatory orders, adequate internal controls, and compliance with SEBI LODR. Shareholding shows Godrej Agrovet holding 67.03% of shares, with 471 permanent employees as of March 31, 2026.

The 32nd Annual General Meeting of Astec LifeSciences Limited is scheduled for 31 July 2026 via video conferencing, with shareholders to vote on adopting FY2025-26 financial statements, reappointing Director Ashok V. Hiremath, and ratifying cost auditor remuneration. The filing details e-voting procedures via NSDL from 26 to 30 July 2026, record date of 24 July 2026, and book closure from 26 to 30 July 2026. It also outlines shareholder communication protocols, including access to the annual report, web-link availability, and instructions for updating personal details or submitting nominations. Sustainability achievements include 26.7% renewable energy usage, 800 MT waste diversion, 17,700 KL water recycling, CDP 'A-' rating, SBTi validation, EcoVadis Gold rating, and zero lost-time injuries. The company emphasizes strategic growth in CDMO capabilities, agrochemical exports (62% of revenue), and ESG compliance, while highlighting risks such as pricing volatility, currency exposure, and customer concentration.